HAEMOPHILUS INFLUENZAE TYPE B is the leading cause of bacterial meningitis in the
United States'2 with an estimated 10,000 to 15,000 cases per year. In addition, this organism …

Although there has been controversy about the protective efficacy of the Haemophilus b
polysaccharide vaccine, this controversy may become moot because of the licensure of …

Hemophilus influenzae type b is a major cause of serious, invasive infections in infants and
children. It causes most cases of bacterial meningitis, nearly all cases of epiglottitis, and a …

Abstract The Committee on Infectious Diseases of the American Academy of Pediatrics
attempts to provide'guidelines that complement the physician's clinical judgment and …

In April 1985, the US FDA licensed Haemophilus influenzae type b polysaccharide vaccine
to protect against invasive disease caused by H influenzae type b. Shortly thereafter, both …

The conjugate Haemophilus influenzae type b (Hib) vaccines are safe and far more
immunogenic among infants and young children than is the unconjugated H. influenzae type …

Haemophilus influenzae type b vaccine was licensed in the United States in the spring of
1985. Prior to licensure, extensive data had accumulated, indicating that this vaccine was …

In recent months much controversy has focused on interpretations of new data concerning
the safety and efficacy of Haemophilus influenzae type b vaccines. 1-3 These controversies …

Abstract Between February 1988 and June 1990, the safety, immunogenicity, and efficacy of
Haemophilus influenzae type b (Hib) oligosaccharide conjugate (HbOC) vaccine was …

In December 1987 the first Haemophilus influenzae type b polysaccharide-protein conjugate
vaccine was licensed for use in the United States., 2 The vaccine is composed of the Hib …